Published: July 2022 | Report Code: 12405 | Available Format: PDF | Pages: 200
The global RNA analysis market is predicted to value $14,909.8 million in 2030, growing from $4,833.4 million in 2021 at a CAGR of 13.3% during 2021–2030. The surge in the preference for personalized medicine, increase in the government funding for omics and pharma and biotech R&D expenditure, rise in the number of RNA sequencing applications, and development of new transcriptomics products by a large number of key players are driving the global RNA analysis/transcriptomics market.
Moreover, the development of several potential technologies, such as antisense technology, SMaRT technology, and RNA interference technology, is predicted to offer substantial opportunities for companies offering RNA-based therapies and vaccines during the forecast period.
Transcriptomics consumables are the largest category in the product segment, and they are expected to retain their position in the coming years owing to the increasing R&D activities in the pharmaceutical industry, as well as the rising government funding for research in life sciences. For instance, in March 2022, the Government of Canada provided federal support of $13.8 million to mobilize genomics through 10 downstream R&D projects.
Transcriptomics software is expected to witness the fastest growth, at a CAGR of more than 14%, during the forecast period. This is largely attributed to the availability of proteomic and genomic data easily in the coming years, which would help researchers conduct studies.
Next-generation sequencing is one of the most-widely used technologies for transcriptomics, accounting a more than 30% market share in 2021, and it is expected to maintain its position throughout this decade. The growth in the field of precision medicine, along with the increase in the number of research studies involving RNA sequencing owing to its advantages over conventional technologies, is credited for the growth of this category. Essentially, the increasing usage of RNA sequencing in cancer and agricultural research is propelling the market growth.
Furthermore, the demand for sequencing-based diagnostics has surged significantly in the past few years, thus resulting in the development of new technologies as well as the increasing demand for equipment such as high-throughput sequencers. Thus, companies are focusing on new product development; for instance, CureVac N.V. has established CureVac RNA Printer GmbH, a subsidiary, to advance The RNA Printer.
Transcriptomics is largely used in drug discovery & development, which accounted for a 29.5% share in 2021. The advent of RNA-based therapeutics is one of the major factors influencing the implementation of RNA analysis in the drug discovery & development process. RNA-based drugs are being explored for difficult-to-treat diseases and those currently without a cure, such as rare genetic disorders, cancer, AIDS, and diabetes. Companies operating in this space are collaborating for the development of drugs based on RNA. For instance, Otsuka Pharmaceutical Co. Ltd. is collaborating with xFOREST Therapeutics Co. Ltd. to create RNA structure-targeted drugs for multiple diseases.
Report Attribute | Details |
Historical Years |
2017-2021 |
Forecast Years |
2022-2030 |
Market Size in 2021 |
$4,833.4 Million |
Revenue Forecast in 2030 |
$14,909.8 Million |
Growth Rate |
13.3% CAGR |
Report Scope |
Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling |
Segments Covered |
By Product; By Technology; By Application; By End User; By Region |
Explore more about this report - Request free sample pages
The North American RNA analysis market share was around 40% in 2021, with the U.S. dominating the market and Canada likely to undergo the faster growth during the forecast period. This growth is attributed to the favorable government initiatives for pharmaceutical R&D, surge in healthcare expenditure, and improvement in the access to advanced healthcare infrastructure. Moreover, the large number of cancer patients and high prevalence of other chronic diseases are boosting the growth. Additionally, the majority of the key pharma and biopharma companies are headquartered in the region, especially in the U.S.
Europe is the second-highest-revenue-generating region, and the industry here is expected to grow at a significant CAGR in the coming years, owing to the non-profit establishments that have combined their financial resources to speed up the development of RNA-based treatments, in response to the growing demand for RNA therapies to address unmet medical needs. Furthermore, the increasing need for personalized medicines, for better clinical results and pharmaceutical safety, has aided the market expansion. The continent is home to a large number of cancer patients who require personalized therapy.
The major countries in the region include Germany, the U.K., France, Spain, and Italy, with Germany dominating the market. Additionally, the U.K. is expected to be the fastest growing owing to government initiatives, such as the one launched in 2020 to establish an advanced genomics-driven healthcare system.
APAC, the third-largest region, is projected to grow at the highest rate during the forecast period, owing to the increasing number of manufacturing plants of biopharmaceutical companies. For instance, Moderna plans to open four new subsidiaries in Taiwan, Singapore, Malaysia, and Hong Kong. Moreover, the target specificity and selectivity of RNAi treatments, along with the usage of virtual drug development models and more-intensive product emphasis versus platform technologies, which enable companies to cut research costs, are driving the market expansion in the region.
The LATAM and MEA regions will also witness substantial growth during the forecast period owing to the increasing incidence of genetic disorders in the region and the lack of proper treatments. In the LATAM region, Brazil accounts for more than half the market share, and Mexico is set to grow at a significant rate. In the MEA region, South Africa has a high potential due to the massive unmet requirement for treatments for a large number of diseases.
In recent years, major players in the RNA analysis market have been actively involved in collaborations and product launches to enhance their capabilities and offerings. For instance:
The study offers a comprehensive market segmentation analysis along with market estimation for the period 2017-2030.
Based on Product
Based on Technology
Based on Application
Based on End-User
Geographical Analysis
The market for RNA analysis solutions generated $4,833.4 million in 2021.
North America leads the RNA analysis industry.
By 2030, the market for RNA analysis solutions will have grown by over $10,000 million.
NGS is the preferred technology in the RNA analysis industry.
The COVID-19 pandemic has boosted the growth of the market for RNA analysis solutions, as RNA analysis is being carried out for understanding the molecular mechanism of this virus.
Get a bespoke market intelligence solution
Want a report tailored exactly to your business strategy?
Request CustomizationWant an insight-rich discussion with the report author?
Speak to AnalystOur dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws